Lilly Looks To Take POINT On Emerging Cancer ... - Scrip

Oct 3, 2023 · Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a …

CouponFollow Extension

$1
OFF

Lilly Looks To Take POINT On Emerging Cancer ... - Scrip

4 weeks from now

Oct 3, 2023 · Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a …

citeline.com

$1
OFF

Eli Lilly To Buy Cancer Specialist Point For $1.4bn - Financial Times

4 weeks from now

Oct 3, 2023 · Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s …

ft.com

$1
OFF

POINT Biopharma To Be Acquired By Eli Lilly For $1.4bn

4 weeks from now

Jacob Van Naarden, president of Loxo@Lilly, the oncology unit of Eli Lilly, commented: "Over the past few years, we have seen how well-designed radiopharmaceuticals can demonstrate …

pharmafocus.com

$1
OFF

Lilly Enters Radiopharmaceuticals With $1.4B Point Acquisition

4 weeks from now

Oct 3, 2023 · Eli Lilly is snapping up Point Biopharma Global for $1.4 billion, marking an official entrance into the radiopharmaceutical cancer therapeutic space. Lilly will acquire all of Point’s ...

fiercebiotech.com

87%
OFF

Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion

4 weeks from now

Oct 3, 2023 · Eli Lilly is purchasing the radiopharmaceutical company for $1.4 billion, or $12.50 a share in cash, 87% higher than Point’s closing price on Monday, the company said.

forbes.com

$1
OFF

Lilly To Enter Radiopharmaceutical Drug Field With $1.4B Point Buyout

4 weeks from now

Oct 3, 2023 · Dive Brief: Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies …

biopharmadive.com

$1
OFF

Lilly Eyes Targeted Cancer Therapies With $1.4 Billion Point …

4 weeks from now

Oct 3, 2023 · Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer.

reuters.com

$1
OFF

Eli Lilly Inks Deal Worth Over $1.1B To Develop ... - Radiology Business

4 weeks from now

May 21, 2024 · Drugmaker Eli Lilly has inked a deal worth over $1 billion to develop new radiopharmaceuticals in concert with biotechnology firm Aktis Oncology. ... president of Lilly …

radiologybusiness.com

FAQs about Lilly Looks To Take POINT On Emerging Cancer ... - Scrip Coupon?

Does Lilly own point Biopharma?

INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. ...

Did Eli Lilly acquire point Biopharma global (PNT)?

INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. ...

Will Eli Lilly buy a treatment for metastatic prostate cancer?

One of the experimental drugs Eli Lilly will acquire is a treatment for metastatic prostate cancer. Dr_Microbe via Getty Images Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. ...

Is Lilly behind the curve in radiopharmaceuticals?

Lilly is slightly behind the curve, striking the deal well after Novartis dove in headfirst to the radiopharmaceuticals space. While Lilly has previously put money behind radiopharmaceutical companies—like supporting Mariana Oncology’s $175 million series B last month—Novartis has made radiopharmaceuticals a pillar of its cancer strategy. ...

Could Lilly & point accelerate the development of radiopharmaceuticals?

Joe McCann, PhD, CEO of POINT, also said in the press release, "The combination of POINT's team, infrastructure and capabilities with Lilly's global resources and experience could significantly accelerate the discovery, development, and global access to radiopharmaceuticals. ...

Why is Lilly partnering with a pharma company to develop radiopharma?

Recent improvements in manufacturing and supplying the complex treatments have boosted investment in the field, drawing interest from large pharma companies like Lilly as well as new drug startups. The Point deal appears to be part of a broader plan by Lilly to build a presence in radiopharma drug development. ...